Suppr超能文献

建立并连续传代来源于 LuCaP 异种移植瘤的细胞培养物。

Establishment and serial passage of cell cultures derived from LuCaP xenografts.

机构信息

Department of Urology, Stanford University, Stanford, California 94305-5118, USA.

出版信息

Prostate. 2013 Sep;73(12):1251-62. doi: 10.1002/pros.22610. Epub 2013 Jun 6.

Abstract

BACKGROUND

LuCaP serially transplantable xenografts derived from primary and metastatic human prostate cancer encompass the molecular and cellular heterogeneity of the disease and are an invaluable resource for in vivo preclinical studies. A limitation of this model, however, has been the inability to establish and passage cell cultures derived from the xenografts. Here, we describe a novel spheroid culture system that supports long-term growth of LuCaP cells in vitro.

METHODS

Xenografts were minced and digested with collagenase. Tissue dissociation was terminated while the majority of cells remained as clusters rather than single cells. The cell clusters were suspended in StemPro medium supplemented with R1881 and Y-27632, a Rho kinase inhibitor, and placed in ultralow attachment dishes for spheroid culture. Serial passage was achieved by partial digestion to small clusters with trypsin/EDTA in the presence of Y-27632. Cell viability, growth and phenotype were monitored with LIVE/DEAD®, MTS, qRT-PCR, and immunocytochemical assays.

RESULTS

Cells from six LuCaP xenografts formed proliferating spheroids that were serially passaged a minimum of three times and cryopreserved. Two of the cell lines, LuCaP 136 and LuCaP 147, were further passaged and characterized. Both expressed biomarkers characteristic of the xenografts of origin, were determined to be of independent origin by STR fingerprinting, and were free of mycoplasma. LuCaP 147 formed tumors similar to the original xenograft when injected into mice.

CONCLUSIONS

The ability to culture LuCaP cells affords new opportunities for fast, cheap, and efficient preclinical studies and extends the value of the LuCaP xenograft models.

摘要

背景

源自原发性和转移性人前列腺癌的 LuCaP 连续可移植异种移植物包含了疾病的分子和细胞异质性,是体内临床前研究的宝贵资源。然而,这种模型的一个局限性是无法建立和传代源自异种移植物的细胞培养物。在这里,我们描述了一种新的球体培养系统,该系统支持 LuCaP 细胞在体外的长期生长。

方法

将异种移植物切碎并用胶原酶消化。在大多数细胞仍然保持为簇而不是单个细胞的情况下,终止组织解离。将细胞簇悬浮在补充有 R1881 和 Rho 激酶抑制剂 Y-27632 的 StemPro 培养基中,并放置在超低附着培养皿中进行球体培养。通过在存在 Y-27632 的情况下用胰蛋白酶/EDTA 将小簇进行部分消化来实现连续传代。通过 LIVE/DEAD®、MTS、qRT-PCR 和免疫细胞化学测定监测细胞活力、生长和表型。

结果

来自六个 LuCaP 异种移植物的细胞形成了增殖球体,可至少连续传代三次并冷冻保存。其中两个细胞系 LuCaP 136 和 LuCaP 147 进一步传代和表征。这两个细胞系都表达了源自异种移植物的特征生物标志物,通过 STR 指纹分析确定为独立起源,并且没有支原体污染。当将 LuCaP 147 注射到小鼠中时,它形成了类似于原始异种移植物的肿瘤。

结论

培养 LuCaP 细胞的能力为快速、廉价和高效的临床前研究提供了新的机会,并扩展了 LuCaP 异种移植物模型的价值。

相似文献

1
Establishment and serial passage of cell cultures derived from LuCaP xenografts.
Prostate. 2013 Sep;73(12):1251-62. doi: 10.1002/pros.22610. Epub 2013 Jun 6.
2
Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.
Clin Exp Metastasis. 2016 Apr;33(4):325-37. doi: 10.1007/s10585-016-9781-2. Epub 2016 Feb 12.
5
Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
Prostate. 2015 Feb 15;75(3):303-13. doi: 10.1002/pros.22916. Epub 2014 Oct 18.
6
Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
PLoS One. 2021 Jan 20;16(1):e0245602. doi: 10.1371/journal.pone.0245602. eCollection 2021.
9
Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming.
J Cell Physiol. 2016 Sep;231(9):2040-7. doi: 10.1002/jcp.25313. Epub 2016 Feb 4.

引用本文的文献

1
Tumor promoting effect of spheroids in an orthotopic prostate cancer mouse model.
Sci Rep. 2024 Apr 17;14(1):8835. doi: 10.1038/s41598-024-59052-0.
2
Prostate cancer research: tools, cell types, and molecular targets.
Front Oncol. 2024 Mar 26;14:1321694. doi: 10.3389/fonc.2024.1321694. eCollection 2024.
5
Geometric tumor embolic budding characterizes inflammatory breast cancer.
Breast Cancer Res Treat. 2023 Feb;197(3):461-478. doi: 10.1007/s10549-022-06819-6. Epub 2022 Dec 6.
6
Experimental in vitro, ex vivo and in vivo models in prostate cancer research.
Nat Rev Urol. 2023 Mar;20(3):158-178. doi: 10.1038/s41585-022-00677-z. Epub 2022 Nov 30.
7
SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
Cell Rep Med. 2022 Feb 2;3(2):100502. doi: 10.1016/j.xcrm.2021.100502. eCollection 2022 Feb 15.
9
3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages.
Int J Mol Sci. 2021 Nov 11;22(22):12200. doi: 10.3390/ijms222212200.
10
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids.
SLAS Discov. 2021 Oct;26(9):1107-1124. doi: 10.1177/24725552211020668. Epub 2021 Jun 11.

本文引用的文献

2
ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells.
Am J Pathol. 2012 Feb;180(2):599-607. doi: 10.1016/j.ajpath.2011.10.036. Epub 2011 Dec 18.
3
Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Cancer Res. 2012 Jan 15;72(2):527-36. doi: 10.1158/0008-5472.CAN-11-3004. Epub 2011 Nov 22.
4
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.
Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17087-92. doi: 10.1073/pnas.1108745108. Epub 2011 Sep 26.
6
Purification and direct transformation of epithelial progenitor cells from primary human prostate.
Nat Protoc. 2011 May;6(5):656-67. doi: 10.1038/nprot.2011.317. Epub 2011 Apr 21.
7
Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer.
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6235-40. doi: 10.1073/pnas.1015938108. Epub 2011 Mar 28.
8
Therapeutic targeting of SPINK1-positive prostate cancer.
Sci Transl Med. 2011 Mar 2;3(72):72ra17. doi: 10.1126/scitranslmed.3001498.
9
High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array.
Analyst. 2011 Feb 7;136(3):473-8. doi: 10.1039/c0an00609b. Epub 2010 Oct 21.
10
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验